Initiator Pharma A/S
12 Jul - 26 Jul 2021Rights issue
Initiator Pharma is a pharmaceutical company based in Aarhus, Denmark. The company’s main clinical fixed assets are IPED2015, intended for patients with erectile dysfunction, and IP2018, for the treatment of psychogenic erectile dysfunction.
The treatments represent both first-class treatments for psychogenic and organic erectile dysfunction, respectively, and are expected to improve the quality of life for a growing number of patients who do not respond or cannot be treated with existing drugs on the market. Initiator Pharma is aimed at patients who do not respond to standardized treatment, a market of about 100 million men by 2025 where current therapies offer very limited opportunities to maintain a normal sex life. The drug candidate IPED2015 works through a new mechanism aimed at central neurotransmitters. In addition to offering a new mechanism with the potential to help non-drug responders, IPED2015 is likely to reduce the side effects of current treatment.
Read more on the company's website
The offer in summary
Record date: 5 July 2021
Terms: Anyone who is a shareholder in the Company on the record date of 5 July 2021 has a preferential right to subscribe for shares in the rights issue in relation to previous shareholdings, whereby one (1) existing share entitles to one (1) subscription right. Shareholders whose shares are registered with Euroclear on the record date receive subscription rights through Euroclear's system. Shareholders whose shares are not registered with Euroclear on the record date are holders of subscription rights via VP Securities' system.
Subscription period: 12 July - 26 July 2021
Subscription price: 3,70 SEK per share for Euroclear shareholders and 2,72 DKK per share for VP Securities shareholders. Brokerage fee may occur.
Volume of issuance: The offer comprises a maximum of 7 958 628 shares, corresponding to approximately 29,4 MSEK
Trading with subscription rights: 12 July - 21 July 2021. Only subscription rights issued through Euroclear will be tradeable on Spotlight Stock Market. Subscription rights must be exercised no later than 26 July 2021 or sold no later than 21 July 2021, in order to not become void or lose their value.
Market: Spotlight Stock Market
Valuation (pre-money): Circa 132,5 MSEK